Clinical Trial: Immune Mobilization of Autologous Peripheral Blood Stem Cells Using Interleukin-2 and GM-CSF

Study Status: Completed
Recruit Status: Completed
Study Type: Interventional

Official Title: Immune Mobilization of Autologous Peripheral Blood Stem Cells Using Interleukin-2 and GM-CSF

Brief Summary: We postulate that the combination of IL-2 and GM-CSF immunotherapy will efficiently mobilize autologous peripheral blood stem cells and activated immune effector cells in patients with a hematologic malignancy. These activated effector cells will improve the immune function of the graft. These hypotheses will be tested using this proposed clinical trial to mobilize autologous peripheral blood stem cells pre-transplantation.

Detailed Summary:
Sponsor: Dartmouth-Hitchcock Medical Center

Current Primary Outcome: Can IL-2 be administered with GM-CSF to efficiently mobilize autologous peripheral blood stem cells. This study will determine the maximum tolerated dose of IL-2 and the optimal biological dose with GM-CSF for stem cell mobilization. [ Time Frame: 5 Years ]

Original Primary Outcome: Same as current

Current Secondary Outcome: Will immune-mobilized stem cell products be well tolerated once infused into patients and will engraft normally following high-dose chemotherapy and APBSCT. [ Time Frame: 5 Years ]

Original Secondary Outcome: Same as current

Information By: Dartmouth-Hitchcock Medical Center

Dates:
Date Received: August 4, 2009
Date Started: January 2003
Date Completion:
Last Updated: May 4, 2016
Last Verified: May 2016